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Chronic allergic contact dermatitis promotes
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Division of Rheumatology, 2Division of Dermatology, Department of Medicine, 3Department of Pathology and Immunology, and 4Howard Hughes Medical Institute,
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Washington University School of Medicine, Saint Louis, Missouri, USA.

Allergic contact dermatitis (ACD) is well recognized as an adverse event associated with implantable medical devices that
contain allergenic materials like nickel; however, other cutaneous consequences of chronic exposure to allergens in implanted
devices are not well understood. Here, we present a clinical case of Marjolin’s ulcer, an invasive squamous cell carcinoma
(SCC) that developed in response to chronic ACD caused by an orthopedic implant. We used a standard murine model of
contact hypersensitivity to determine whether chronic ACD promotes skin carcinogenesis. Chronic application of 1-fluoro2,4-dinitrobenzene (DNFB) to carcinogen-treated skin led to the development of papillomas and aggressive SCC. DNFBdriven chronic ACD was marked by type 2 inflammation, which mediated skin carcinogenesis, as mice unable to mount an
inflammatory response were less likely to develop skin tumors. Importantly, we found similar tumor-promoting inflammation
surrounding the SCC in our patient. Our findings demonstrate that chronic ACD caused by constant exposure to an allergen can
promote tumorigenesis at skin sites with preexisting cancer-initiated cells. Moreover, our results suggest that patients with
implantable devices placed in close proximity to the skin should be monitored for ACD and highlight the importance of patch
testing prior to the placement of such devices.

Introduction

Implantable devices like orthopedic, dental, and cardiac implants
are an increasingly indispensable part of medical therapeutics.
With regard to orthopedic devices, over 1 million lower-extremity
joint replacements are performed each year in the United States,
and this number is predicted to rise in the future due to the aging
population, increase in the rate of obesity, and expansion of medical indications (1). These devices contain metal alloys including nickel, cobalt, and chromium that provide their strength and
long-term durability. However, allergy to metals included in the
implants is commonly seen, with about 20% of the US population being allergic to nickel (2). Chronic inflammation from metal
joint replacements may cause complications at the implant site,
which mostly present as chronic joint pain, swelling, loosening,
and joint failure (3). For other implants placed in close proximity
to the skin, allergic contact dermatitis (ACD) can ensue in 0.1% to
5% of metal implant cases (4, 5). The mechanism of acute ACD is
well understood and involves a type IV hypersensitivity reaction
mediated by Th1 cells responding to hapten-modified proteins (6),
while chronic ACD results in Th2-polarized inflammation (7, 8).
The long-term consequences of chronic ACD caused by allergenic
metal implants are poorly understood.
Here, we present a clinical case of Marjolin’s ulcer, an invasive
squamous cell carcinoma (SCC) that developed in the context of
nickel allergy from a subcutaneous metal implant. Using animal
models, we demonstrate that prolonged ACD markedly enhances
the development of skin cancer at the skin site exposed to a carcinConflict of interest: The authors have declared that no conflict of interest exists.
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ogen. Further, we show that chronic ACD has the cardinal features
of a protumorigenic inflammatory environment and is responsible
for this tumor promotion.

Results and Discussion

A 46-year-old white female with no history of skin cancer had an
ankle fracture 3 years earlier, which was repaired with open reduction and internal fixation with metal rod placement on the lateral
aspect of her fibula for stabilization. After the initial surgery, the
patient developed a nonhealing skin lesion on her left ankle overlying the metal implant and the surgical wound site. Subsequently,
she was found to be allergic to the nickel in the metal implant (Figure 1A). The implant was removed a year after the initial surgery,
but the skin lesion persisted. When the patient presented to us
with a 3-year history of the ulcerated skin lesion, she had significant erythema, pain, and oozing at the lesion site and evidence of
chronic sun exposure in the nonlesional skin (Figure 1B). A biopsy
showed a well-differentiated but invasive SCC consistent with a
Marjolin’s ulcer (Figure 1C). Due to the depth of invasion and concern for metastasis, the patient underwent a PET-CT scan, which
was negative (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI77843DS1). The SCC
was surgically excised with a clear margin without signs of recurrence over a 2-year follow-up period.
The development of a high-risk SCC in an individual without
a history of skin cancer strongly suggested that the chronic ACD
surrounding the surgical wound on the patient’s sun-exposed
skin culminated in cancer formation. To determine whether
chronic ACD can synergize with the surgical wound to promote
skin tumorigenesis, we examined the tumor-promoting potential of contact hypersensitivity in mice. Due to species-specific
jci.org   Volume 124   Number 11   November 2014
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Figure 1. Chronic ACD promotes skin tumorigenesis. (A–C) Clinical case of an invasive SCC that developed in the context of ACD to nickel is shown.
(A) Skin-patch test result indicated nickel allergy. (B) SCC lesion on the patient’s left lateral ankle. Note the solar lentigines on the patient’s leg
that are a sign of chronic sun exposure. Also, there were no signs of vascular compromise or stasis changes (arrow marks the biopsy site). (C) Punch
biopsy of the lesion demonstrated a well-differentiated, but invasive, SCC (scale bar: 100 μm), consistent with Marjolin’s ulcer. (D) Experimental
design used to investigate whether chronic ACD synergizes with the surgical wound to promote tumor development. (E) Time to tumor onset and
(F) average number of tumors per animal for each group. Regardless of the presence of a surgical wound, animals chronically treated with DNFB
developed skin tumors with short latency (*P < 0.001 by log-rank test) and increasing tumor counts over time (*P < 0.05 starting from week 7 by
Student’s t test). No skin tumors developed in the acetone-treated group, despite carcinogen exposure. Age-matched FVB female mice were used
in this study; n = 6 per group.

susceptibility, mice do not respond to nickel, and we therefore
studied hapten-induced contact hypersensitivity, which induces
similar inflammatory responses (Figure 1D and refs. 9, 10). First,
we exposed a group of age-matched female FVB mice to acetone (carrier) or 1-fluoro-2,4-dinitrobenzene (DNFB) on their
abdomen at day 0. One week later, their back skin was treated
with a single dose of 7,12-dimethylbenz(a)anthracene (DMBA),
a commonly used carcinogen that mimics the cancer-initiating
effect of sun exposure (11–13). The following week, the animals
were randomized for surgical wounding and placed into 1 of the
following 3 groups: (a) acetone (carrier) treatment plus surgical
wounding; (b) DNFB treatment; or (c) DNFB treatment plus surgical wounding. After surgical incision, suture placement, and
the first topical treatment, the animals were treated every 2 to
3 days with DNFB or acetone for 14 weeks and followed for an
additional 9 weeks (Figure 1D). Animals receiving DNFB developed skin tumors with a short latency, while none of the animals
treated with acetone alone developed tumors, despite the carcinogen (P < 0.01, Figure 1, E and F). Notably, the tumor-promoting
effect of the allergen was dominant and masked any contribution from a surgical wound. In addition, skin tumors that formed
during the allergen treatment period persisted after treatments
were stopped (Figure 1F). Although the DNFB-treated animals
each developed a few skin tumors (Figure 1F), they experienced a
high rate of tumor progression from papilloma to SCC, leading to
their early demise (P < 0.05; Supplemental Figure 2A). The SCCs
were well-to-moderately differentiated invasive carcinomas
with aggressive behavior reminiscent of the SCC in our clinical
patient (Supplemental Figure 2B). Thus, chronic ACD markedly
enhanced tumor formation.
5038
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To determine whether DNFB-induced chronic ACD results
in a tumor-promoting environment, we analyzed the dorsal skin
of animals treated with DNFB versus acetone at the end of the
chronic allergen treatment period (Figure 1D). The DNFB-treated
skin showed marked epidermal hyperplasia, with dense dermal
inflammation compared with that of the acetone-treated controls
(Figure 2A). Chronic ACD in our animals was associated with a
Th2-dominant immune response, characterized by abundant production of Il4 but not Ifng (Figure 2B and refs. 14, 15). This is consistent with previous studies demonstrating the switch from type
1 inflammation in acute ACD to type 2 in the chronic phase (7, 8).
In addition, the DNFB-treated skin expressed significantly higher
levels of Il6 compared with levels detected in the acetone-treated
controls (Figure 2C and ref. 16). In addition to CD4+ T cells, the
number of mast cells, alternatively activated (M2) macrophages
(F4/80+CD206+), and blood vessels was markedly increased upon
chronic DNFB treatment (Figure 2D and Supplemental Figure 3).
Each of these factors has been implicated in tumor promotion (14,
17, 18). Therefore, chronic ACD results in the critical elements of a
tumor-promoting inflammatory environment in the skin.
To confirm that the tumor-promoting effect of DNFB is driven
by chronic ACD and not by a direct effect of the chemical on
keratinocytes (tissue source of the tumor) (19), we studied Rag1–/–
(Rag-KO) and Rag2–/–, γc–/– (Ragγc-KO) animals (Figure 1D) that
lack adaptive and innate immune cells implicated in the induction
of ACD (20, 21). Although WT, Rag-KO, and Ragγc-KO animals
showed a similar degree of hair loss and skin irritation in response
to DNFB (Supplemental Figure 4), Rag-KO and Ragγc-KO animals
developed significantly less inflammation in response to chronic
DNFB treatment (Supplemental Figure 5A). Likewise, Rag-KO
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Figure 2. Chronic ACD manifests
protumorigenic factors and mediates
the tumor-promoting effects of DNFB.
(A) Representative H&E-stained skin
images from mice treated with DNFB
for 14 weeks and their acetone-treated
controls (scale bars: 100 μm). Note the
extent of epidermal hyperplasia and dermal inflammation in the DNFB-treated
skin. (B) Quantitative real-time PCR
analysis of cytokine expression by major
Th cell subtypes performed on skin from
mice treated with DNFB for 14 weeks
compared with cytokine expression in
acetone-treated controls (n = 4 in each
group; *P < 0.05 by Student’s t test). (C)
Il6 expression in skin treated with DNFB
for 14 weeks was compared with that in
skin of acetone-treated controls (n = 4
in each group; *P < 0.05 by Student’s t
test). (D) Average number of mast cells
in 6 random high-power microscopic
fields (HPF) of skin from animals treated
chronically with DNFB was compared
with that of acetone-treated mice
(*P < 0.05 by Student’s t test). Representative images of toluidine blue–
stained skin sections show increased
number, size, and granularity of mast
cells in DNFB-treated skin (scale bar:
50 μm). (E and F) Tumor outcome of
Rag-KO, Ragγc-KO, and WT animals in
response to DNFB plus surgical wounding
(following the protocol described in Figure 1D). (E) Shown are the time to tumor
onset (*P < 0.01 by log-rank test) and (F)
average number of tumors per animal for
each of the 4 groups (*P < 0.05 starting
from week 10 by Student’s t test). Agematched C57BL/6 female mice were used
in this study; n > 7 per group.

and Ragγc-KO animals treated with DNFB failed to develop any
significant epidermal hyperplasia, accumulation of mast cells, M2
macrophages, or blood vessels in their skin compared with what
we observed in the DNFB-treated WT animals (Supplemental
Figure 5). Importantly, Rag-KO and Ragγc-KO animals treated
with DNFB and surgical wounding showed a significantly lower
propensity for skin tumor development compared with their agematched WT animals on a C57BL/6 genetic background (P < 0.01,
Figure 2, E and F). These findings demonstrate that chronic exposure to a hapten-producing allergen induces tumor-promoting
inflammation in the skin.
Finally, we examined the immune environment of the SCC
that developed in our clinical case. A dense dermal inflammation
was present, surrounding the focus of skin cancer, which was dominated by Th2 cells with characteristic expression of GATA3 but not
T-bet (Figure 3A). In addition, the other cellular hallmarks of the
tumor-promoting chronic ACD environment were present in the
patient’s lesional skin, as shown by a marked increase in blood vessels, M2 macrophages, and mast cells (Figure 3, B and C, and Supplemental Figures 6 and 7). Importantly, the inflammation was not

confined to the local environment of the SCC and extended with
similar intensity into the cancer-free margins of the excision (Figure 3C and Supplemental Figure 7). These features strongly suggest
that the patient’s inflammation was the driver of the carcinogenesis
and not secondary or reactive to cancer development itself.
Our findings provide clear evidence for the tumor-promoting property of chronic ACD. Chronic ACD can thus lead to the
development of Marjolin’s ulcer–like invasive SCC in areas where
a significant burden of cancer-initiated cells is present (i.e., sunor carcinogen-exposed skin). The chronic nature of ACD caused
by implantable devices that are placed adjacent to sun-exposed
skin can thus provide this “perfect storm,” as seen in our clinical
patient. Although rare, the morbidity and mortality associated
with such aggressive cancers highlight the importance of skinpatch testing prior to the placement of implantable devices, especially in patients with known metal allergies (22).
Interestingly, skin cancer development in the context of metal
allergy has also been observed with metal dental restorations (23,
24). In addition, there are multiple clinical case reports of SCC
development in tattoos, and ACD due to metals used in tattoo dyes
jci.org   Volume 124   Number 11   November 2014
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Figure 3. Tumor-promoting inflammation is associated with patient’s SCC. (A) H&E staining of the punch biopsy specimen highlights the extent of
inflammation associated with SCC compared with that in normal skin. CD3, GATA3, and T-bet staining of the patient’s SCC shows significant accumulation
of GATA3+ T cells (i.e., Th2 cells) in the dermis surrounding the SCC (quantified as the percentage of CD3+ cells counted in 6 random HPFs). (B) CD31 staining
marks the vascular density surrounding the patient’s SCC compared with that in the normal skin. (C) Average number of mast cells in 6 random HPFs near
the site of SCC (Punch Bx) and beyond at the excision margins was compared with the number of mast cells in the normal skin. The increased number of
mast cells in the excision margins indicates that the patient’s skin inflammation extended beyond the cancer site. Representative images are shown.
*P < 0.05. Scale bars: 100 μm; 10 μm (enlarged images in A and inset in B).

has been reported to precede the development of such cancers (25,
26). Our findings provide a mechanistic explanation for skin cancer development in these clinical contexts. Taken together, our
study describes the mechanism of a severe adverse event associated with implantable materials and calls for close monitoring of
patients receiving these implants to avoid chronic ACD and the
possibility of developing SCC.

Methods

Patient samples. The initial punch biopsy of the SCC and the completely
excised lesion with clear margins were fixed in formalin and embedded in paraffin. H&E staining was performed using Tissue-Tek Prisma
Stainer (Sakura Finetek USA). Formalin-fixed, paraffin-embedded
tissue sections (4-μm) were immunostained using a Ventana ULTRA
automated immunostainer (Ventana Medical Systems).
Statistics. To test the significance between study groups, we used
a log-rank test for tumor onset and survival data and a 2-tailed Student’s t test for tumor counts and other quantitative measurements.
A P value of less than 0.05 was considered statistically significant. All
bar graphs show the mean + SD.
Study approval. The clinical study was approved by the IRB of
Washington University, and written informed consent was obtained to
5040
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publish the patient’s photographs and study her skin cancer. All animal
studies were approved by the IACUC of Washington University.
Refer to the Supplemental Methods for a further description of the
methods.
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